Felbinac intravenous - Shijiazhuang Yiling Pharmaceutical/Guangdong Zhongke Drug Research & Development

Drug Profile

Felbinac intravenous - Shijiazhuang Yiling Pharmaceutical/Guangdong Zhongke Drug Research & Development

Alternative Names: Felbinac trometamol

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shijiazhuang Yiling Pharmaceutical
  • Class Nonsteroidal anti-inflammatories; Phenylacetates
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Inflammation; Pain

Most Recent Events

  • 17 Jul 2017 Phase-I for Inflammation (In volunteers) in China (IV) (NCT03235778)
  • 17 Jul 2017 Phase-I for Pain (In volunteers) in China (IV) (NCT03235778)
  • 30 May 2016 Chemical information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top